schliessen

Filtern

 

Bibliotheken

Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration

Deferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with β-thalassemia major. However, the pharmacokinetic (PK) disposition of DEFR and the iron–DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear. Chromatographic analysis... Full description

Journal Title: Clinical Therapeutics 01 August 2015, Vol.37(8), pp.1751-1760
Main Author: Lu, Meng-Yao
Other Authors: Wang, Ning , Wu, Wen-Hsin , Lai, Cheng-Wei , Kuo, Pei-Hsin , Chiang, Po-Hung , Lin, Kai-Hsin , Wu, Tzu-Hua
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0149-2918 ; E-ISSN: 1879-114X ; DOI: 10.1016/j.clinthera.2015.05.506
Link: http://dx.doi.org/10.1016/j.clinthera.2015.05.506
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_clinthera_2015_05_506
title: Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
format: Article
creator:
  • Lu, Meng-Yao
  • Wang, Ning
  • Wu, Wen-Hsin
  • Lai, Cheng-Wei
  • Kuo, Pei-Hsin
  • Chiang, Po-Hung
  • Lin, Kai-Hsin
  • Wu, Tzu-Hua
subjects:
  • Deferasirox
  • Deferasirox–Iron Complex
  • Dosing Schedule
  • Hplc-Uv
  • Pharmacokinetics
  • Deferasirox
  • Deferasirox–Iron Complex
  • Dosing Schedule
  • Hplc-Uv
  • Pharmacokinetics
  • Medicine
  • Pharmacy, Therapeutics, & Pharmacology
ispartof: Clinical Therapeutics, 01 August 2015, Vol.37(8), pp.1751-1760
description: Deferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with β-thalassemia major. However, the pharmacokinetic (PK) disposition of DEFR and the iron–DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear. Chromatographic analysis was performed using a solvent delivery system coupled to an HPLC-UV detector to determine the steady-state concentrations of DEFR (CDEFR) and Fe-(DEFR)2 (CFe-[DEFR]2) in β-thalassemia major patients (n = 8) following either once-daily or BID dosing, during which the PK parameters of the 2 dosing schedules were compared. An HPLC-UV system for the analysis of blood samples following solid-phase extraction was validated. Patients who received 40 mg/kg of DEFR had higher mean CDEFR and CFe-[DEFR]2 values at all sampling times. However, concentrations of iron-DEFR complex were similar in patients who received 30 or 40 mg/kg of DEFR in the once-daily...
language: eng
source:
identifier: ISSN: 0149-2918 ; E-ISSN: 1879-114X ; DOI: 10.1016/j.clinthera.2015.05.506
fulltext: fulltext
issn:
  • 0149-2918
  • 01492918
  • 1879-114X
  • 1879114X
url: Link


@attributes
ID1849789604
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_clinthera_2015_05_506
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_clinthera_2015_05_506
sourcesystemPC
dbid
0--K
1--M
2.FO
3.~1
41P~
51~.
6457
74G.
87-5
98P~
10AABNK
11AAEDT
12AAKOC
13AAOAW
14AAQFI
15AATCM
16ABBQC
17ABFNM
18ABLVK
19ABMZM
20ABYKQ
21ABZDS
22ACDAQ
23ACRLP
24ADALY
25AEKER
26AEVXI
27AFKWA
28AFTJW
29AFXIZ
30AGUBO
31AGYEJ
32AIKHN
33AITUG
34AJBFU
35AJOXV
36AJRQY
37AJUYK
38ALCLG
39AMFUW
40AMRAJ
41ANZVX
42BLXMC
43BNPGV
44EO8
45EO9
46EP2
47EP3
48FDB
49FIRID
50FNPLU
51G-Q
52GBLVA
53J1W
54KOM
55LCYCR
56OAUVE
57OD~
58OGGZJ
59OO0
60P-8
61P-9
62PC.
63Q38
64RPZ
65SCC
66SDF
67SDG
68SEL
69SES
70SSH
71SSP
72SSZ
73T5K
74Z5R
75~G-
pqid1712843860
galeid432084605
display
typearticle
titleSimultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
creatorLu, Meng-Yao ; Wang, Ning ; Wu, Wen-Hsin ; Lai, Cheng-Wei ; Kuo, Pei-Hsin ; Chiang, Po-Hung ; Lin, Kai-Hsin ; Wu, Tzu-Hua
ispartofClinical Therapeutics, 01 August 2015, Vol.37(8), pp.1751-1760
identifier
subjectDeferasirox ; Deferasirox–Iron Complex ; Dosing Schedule ; Hplc-Uv ; Pharmacokinetics ; Deferasirox ; Deferasirox–Iron Complex ; Dosing Schedule ; Hplc-Uv ; Pharmacokinetics ; Medicine ; Pharmacy, Therapeutics, & Pharmacology
descriptionDeferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with β-thalassemia major. However, the pharmacokinetic (PK) disposition of DEFR and the iron–DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear. Chromatographic analysis was performed using a solvent delivery system coupled to an HPLC-UV detector to determine the steady-state concentrations of DEFR (CDEFR) and Fe-(DEFR)2 (CFe-[DEFR]2) in β-thalassemia major patients (n = 8) following either once-daily or BID dosing, during which the PK parameters of the 2 dosing schedules were compared. An HPLC-UV system for the analysis of blood samples following solid-phase extraction was validated. Patients who received 40 mg/kg of DEFR had higher mean CDEFR and CFe-[DEFR]2 values at all sampling times. However, concentrations of iron-DEFR complex were similar in patients who received 30 or 40 mg/kg of DEFR in the once-daily...
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1016/j.clinthera.2015.05.506$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Lu, Meng-Yao
1Wang, Ning
2Wu, Wen-Hsin
3Lai, Cheng-Wei
4Kuo, Pei-Hsin
5Chiang, Po-Hung
6Lin, Kai-Hsin
7Wu, Tzu-Hua
titleSimultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
description

Deferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with β-thalassemia major. However, the pharmacokinetic (PK) disposition of DEFR and the iron–DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear.

Chromatographic analysis was performed using a solvent delivery system coupled to an HPLC-UV detector to determine the steady-state concentrations of DEFR (CDEFR) and Fe-(DEFR)2 (CFe-[DEFR]2) in β-thalassemia major patients (n = 8) following either once-daily or BID dosing, during which the PK parameters of the 2 dosing schedules were compared.

An HPLC-UV system for the analysis of blood samples following solid-phase extraction was validated. Patients who received 40 mg/kg of DEFR had higher mean CDEFR and CFe-[DEFR]2 values at all sampling times. However, concentrations of iron-DEFR complex were similar in patients who received 30 or 40 mg/kg of DEFR in the once-daily...

subject
0Deferasirox
1Deferasirox–Iron Complex
2Dosing Schedule
3Hplc-Uv
4Pharmacokinetics
5Medicine
6Pharmacy, Therapeutics, & Pharmacology
general
0English
1Elsevier Inc
210.1016/j.clinthera.2015.05.506
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_clinthera_2015_05_506
issn
00149-2918
101492918
21879-114X
31879114X
rsrctypearticle
creationdate2015
addtitleClinical Therapeutics
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
3.~1
41P~
51~.
6457
74G.
87-5
98P~
10AABNK
11AAEDT
12AAKOC
13AAOAW
14AAQFI
15AATCM
16ABBQC
17ABFNM
18ABLVK
19ABMZM
20ABYKQ
21ABZDS
22ACDAQ
23ACRLP
24ADALY
25AEKER
26AEVXI
27AFKWA
28AFTJW
29AFXIZ
30AGUBO
31AGYEJ
32AIKHN
33AITUG
34AJBFU
35AJOXV
36AJRQY
37AJUYK
38ALCLG
39AMFUW
40AMRAJ
41ANZVX
42BLXMC
43BNPGV
44EO8
45EO9
46EP2
47EP3
48FDB
49FIRID
50FNPLU
51G-Q
52GBLVA
53J1W
54KOM
55LCYCR
56OAUVE
57OD~
58OGGZJ
59OO0
60P-8
61P-9
62PC.
63Q38
64RPZ
65SCC
66SDF
67SDG
68SEL
69SES
70SSH
71SSP
72SSZ
73T5K
74Z5R
75~G-
startdate20150801
enddate20150801
lsr40Clinical Therapeutics, 01 August 2015, Vol.37 (8), pp.1751-1760
doi10.1016/j.clinthera.2015.05.506
citationpf 1751 pt 1760 vol 37 issue 8
lsr30VSR-Enriched:[galeid, pqid]
sort
titleSimultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
authorLu, Meng-Yao ; Wang, Ning ; Wu, Wen-Hsin ; Lai, Cheng-Wei ; Kuo, Pei-Hsin ; Chiang, Po-Hung ; Lin, Kai-Hsin ; Wu, Tzu-Hua
creationdate20150801
lso0120150801
facets
frbrgroupid4109480497603372140
frbrtype5
newrecords20190904
languageeng
topic
0Deferasirox
1Deferasirox–Iron Complex
2Dosing Schedule
3Hplc-Uv
4Pharmacokinetics
5Medicine
6Pharmacy, Therapeutics, & Pharmacology
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Lu, Meng-Yao
1Wang, Ning
2Wu, Wen-Hsin
3Lai, Cheng-Wei
4Kuo, Pei-Hsin
5Chiang, Po-Hung
6Lin, Kai-Hsin
7Wu, Tzu-Hua
jtitleClinical Therapeutics
creationdate2015
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Lu
1Wang
2Wu
3Lai
4Kuo
5Chiang
6Lin
aufirst
0Meng-Yao
1Ning
2Wen-Hsin
3Cheng-Wei
4Pei-Hsin
5Po-Hung
6Kai-Hsin
7Tzu-Hua
auinitM
auinit1M
au
0Lu, Meng-Yao
1Wang, Ning
2Wu, Wen-Hsin
3Lai, Cheng-Wei
4Kuo, Pei-Hsin
5Chiang, Po-Hung
6Lin, Kai-Hsin
7Wu, Tzu-Hua
atitleSimultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
jtitleClinical Therapeutics
risdate20150801
volume37
issue8
spage1751
epage1760
pages1751-1760
issn0149-2918
eissn1879-114X
formatjournal
genrearticle
ristypeJOUR
abstract

Deferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with β-thalassemia major. However, the pharmacokinetic (PK) disposition of DEFR and the iron–DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear.

Chromatographic analysis was performed using a solvent delivery system coupled to an HPLC-UV detector to determine the steady-state concentrations of DEFR (CDEFR) and Fe-(DEFR)2 (CFe-[DEFR]2) in β-thalassemia major patients (n = 8) following either once-daily or BID dosing, during which the PK parameters of the 2 dosing schedules were compared.

An HPLC-UV system for the analysis of blood samples following solid-phase extraction was validated. Patients who received 40 mg/kg of DEFR had higher mean CDEFR and CFe-[DEFR]2 values at all sampling times. However, concentrations of iron-DEFR complex were similar in patients who received 30 or 40 mg/kg of DEFR in the once-daily...

pubElsevier Inc
doi10.1016/j.clinthera.2015.05.506
lad01Clinical Therapeutics
date2015-08-01